A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

The study revealed the following findings: 36.3% of psoriasis patients had elevated high-sensitivity C-reactive protein ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

The study reveals that patients with both T2D and psoriasis face a significantly elevated risk of developing renal conditions ...

A new study reveals psoriasis may increase the risk of obesity and fatty liver despite skin improvements Learn why managing ...

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, inflammation can linger, leading to broader health implications such as obesity ...

Inflammation tends to remain in people with psoriasis, despite their skin responding well to treatment with biologics, latest evidence has revealed. Residual inflammation is associated with an ...

A new study highlights a significant medical concern for individuals suffering from psoriasis, revealing that even when skin ...

Psoriasis, with its systemic inflammatory nature, high risk of cardiovascular disease, and frequent use of biologic drugs, ...